(Q35033184)

English

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

0 references

1 reference

based on heuristic

inferred from title

postmenopausal osteoporosis

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

0 references

author name string

H G Bone

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

D W Dempster

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

J A Eisman

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

S L Greenspan

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

M R McClung

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

T Nakamura

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

S Papapoulos

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

W J Shih

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

A Rybak-Feiglin

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

A C Santora

10

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

N Verbruggen

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

A T Leung

12

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

A Lombardi

13

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

language of work or name

0 references

publication date

29 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Osteoporosis International

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

699-712

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

29 November 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s00198-014-2944-6

0 references

The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

New targets for intervention in the treatment of postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Issues in modern bone histomorphometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

The amazing osteocyte

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Denosumab and bisphosphonates: different mechanisms of action and effects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Osteoclast-derived activity in the coupling of bone formation to resorption.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Osteoclast differentiation and activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Vertebral fracture assessment using a semiquantitative technique.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Comparative analysis of two rates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

8 July 2018

Bisphosphonate effects and the bone remodeling transient.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2944-6

21 January 2018

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2944-6

21 January 2018

Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2944-6

21 January 2018

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2944-6

21 January 2018

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2944-6

21 January 2018

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2944-6

21 January 2018

Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

25 October 2018

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312384

25 October 2018

Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2944-6

21 January 2018

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2944-6

21 January 2018

Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differing effects of denosumab and alendronate on cortical and trabecular bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Study design in osteoporosis: a European perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/25432773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00198-014-2944-6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35033184&oldid=1859510094"